AI Insight
Researchers are applying artificial intelligence to tuberculosis drug discovery to address the challenge of narrowing down thousands of potential drug compounds identified through screening. The traditional screening process generates an overwhelming number of candidate compounds, many of which prove to be inefficient investments of time and resources. AI tools are being developed to more effectively prioritize which compounds warrant further investigation and development.
Why it matters
This approach could significantly accelerate tuberculosis drug development by reducing wasted effort on compounds unlikely to succeed, potentially leading to faster availability of new treatments for a disease that remains a major global health threat. The methodology may also be applicable to drug discovery for other infectious diseases.
Understand the Science
When researchers screen potential tuberculosis drugs, they often end up with too many options. Some look promising but later prove to be costly dead ends. “We might get thousands of compounds from a screen and then have to decide which one are we going to work on?” said James Sacchettini, Ph.D., the Rodger J. Wolfe-Welch Foundation Chair in Science, Texas A&M AgriLife Research scientist and professor in the Texas A&M College of Agriculture and Life Sciences Department of Biochemistry and Biophysics and College of Arts and Sciences Department of Chemistry.